What question did this study set out to answer?

To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea.

May 8, 2012Diabetes Obesity and MetabolismOpen Access

Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)

View Full Paper

Ask AI

Bookmark

Authors

YSYutaka SeinoKansai Electric Power (Japan)KMKyung Wan MinEulji University ENElisabeth NiemoellerSanofi (Germany)

Discussion

Member takes

Implication

Randomized double-blind trial demonstrates improved glycemic control with once-daily lixisenatide in Asian adults with type 2 diabetes, indicating its efficacy as an add-on to basal insulin.

Key Points

To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea.
Conducted a 24-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial across Japan, Republic of Korea, Taiwan, and the Philippines.
Randomized patients with baseline HbA1c 8.53% to receive either once-daily lixisenatide titrated to 20 µg (N = 154) or placebo (N = 157) alongside basal insulin ± sulfonylurea.
Lixisenatide produced a significant reduction in HbA1c at week 24 compared to placebo (LS mean difference vs. placebo = -0.88%, 95% CI: -1.116 to -0.650; p < 0.0001), with more patients achieving HbA1c <7.0% (35.6% vs. 5.2%) and ≤6.5% (17.8% vs. 1.3%).
Significant improvements occurred with lixisenatide in 2-hour postprandial plasma glucose, glucose excursion, 7-point self-monitored blood glucose, and fasting plasma glucose.
Serious adverse events occurred in 6.5% (10/154) of lixisenatide versus 5.7% (9/157) of placebo recipients, while symptomatic hypoglycemia occurred in 42.9% versus 23.6% overall but was comparable without sulfonylureas (32.6% vs. 28.3%), with zero severe episodes.

Cite This Study

Seino et al. (2012) studied this question.

synapsesocial.com/papers/6a7c97856111ec194fa8acd5 https://doi.org/10.1111/j.1463-1326.2012.01618.x

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates improved glycemic control with once-daily lixisenatide in Asian adults with type 2 diabetes, indicating its efficacy as an add-on to basal insulin.

Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)

Discussion

Member takes

Implication

Key Points

Cite This Study

Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider